Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin

Journal of Extracellular Vesicles

Volumn 5, Issue 1, 2016, Pages

  Martins Marques, Tania ^a,b   Pinho, Maria Joao ^a,b   Zuzarte, Monica ^a,b   Oliveira, Carla ^c,d,e   Pereira, Paulo ^f   Sluijter, Joost P G ^g,h   Gomes, Celia ^a,b,i   Girao, Henrique ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e University of Porto   (Portugal)

^f NOVA MEDICAL SCHOOL   (Portugal)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

ⁱ UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cancer; Cardioprotection; Drug delivery; Extracellular vesicles; Intercellular communication

Indexed keywords

CONNEXIN 43; DOXORUBICIN; DRUG CARRIER; LUCIFERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; EMBRYO; EXOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN FUNCTION;

EID: 85015307223     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.3402/jev.v5.32538     Document Type: Article

References (46)

1. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015;77:13-27.
2. Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013;2:20389, doi: http://dx.doi.org/10.3402/jev.v2i0.20389
3. György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015;55: 439-64.
4. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21:185-91.
5. Tickner JA, Urquhart AJ, Stephenson S-A, Richard DJ, O'Byrne KJ. Functions and therapeutic roles of exosomes in cancer. Front Oncol. 2014;4:127.
6. Mulcahy LA, Pink RC, Carter DRF. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3: 24641, doi: http://dx.doi.org/10.3402/jev.v3.24641
7. Soares AR, Martins-Marques T, Ribeiro-Rodrigues T, Ferreira JV, Catarino S, Pinho MJ, et al. Gap junctional protein Cx43 is involved in the communication between extracellular vesicles and mammalian cells. Sci Rep. 2015;5:13243.
8. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19:1769-79.
9. Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, et al. Genetically engineered microvesicles carrying suicide mRNA/Protein inhibit schwannoma tumor growth. Mol Ther. 2013;21:101-8.
10. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35:2383-90.
11. Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta. 2014;1846:75-87.
12. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:547-58.
13. Toffoli G, Hadla M, Corona G, Caligiuri I, Palazzolo S, Semeraro S, et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine (Lond). 2015 [cited 2016 May 5]. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/26420143
14. Lener T, Gioma M, Aigner L, Börger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087, doi: http://dx.doi.org/10.3402/jev.v4.30087
15. Elzarrad MK, Haroon A, Willecke K, Dobrowolski R, Gillespie MN, Al-Mehdi A-B, et al. Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. BMC Med. 2008;6:20.
16. McLachlan E, Shao Q, Laird DW. Connexins and gap junctions in mammary gland development and breast cancer progression. J Membr Biol. 2007;218:107-21.
17. Ferreira-Teixeira M, Parada B, Rodrigues-Santos P, Alves V, Ramalho JS, Caramelo F, et al. Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. Oncotarget. 2015;6:36185-201.
18. Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JVMG, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/b-catenin signaling. Cancer Lett. 2016; 370:286-95.
19. Lim E, Modi KD, Kim J. In vivo bioluminescent imaging of mammary tumors using IVIS spectrum. J Vis Exp. 2009. pii: 1210. [cited 2016 May 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19404236
20. Théry C, Amigorena S, Raposo G, Clayton A, Théry C, Amigorena S, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. In: Current protocols in cell biology. Hoboken, NJ: Wiley; 2006. p. 3.22.1- 3.22.29. [cited 4 May 2016]. Available from: http://doi.wiley.com/10.1002/0471143030.cb0322s30
21. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan MLG, Karlsson JM, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119:756-66.
22. Johnson S, Nguyen V, Coder D, Johnson S, Nguyen V, Coder D. Assessment of cell viability. In: Current protocols in cytometry. Hoboken, NJ: Wiley; 2013. p. 9.2.1-9.2.26. [cited 2016 Jun 6]. Available from: http://doi.wiley.com/10.1002/0471142956.cy0902s64
23. Strober W. Trypan blue exclusion test of cell viability. In: Current protocols in immunology. Hoboken, NJ: Wiley; 2015. p. A3.B.1-A3.B.3. [cited 2016 Jun 6]. Available from: http:// doi.wiley.com/10.1002/0471142735.ima03bs111
24. Butler M, Spearman M, Braasch K. Monitoring cell growth, viability, and apoptosis. Methods Mol Biol. 2014;1104:169-92.
25. Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. In: Checkpoint controls and cancer. Totowa, NJ: Humana Press. p. 301-12. [cited 2016 May 5]. Available from: http://link.springer.com/10.1385/1-59259-811-0:301
26. Jain P, Worthylake RA, Alahari SK. Quantitative analysis of random migration of cells using time-lapse video microscopy. J Vis Exp. 2012;63:e3585.
27. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1: 2315-9.
28. Martins-Marques T, Catarino S, Zuzarte M, Marques C, Matafome P, Pereira P, et al. Ischemia-induced autophagy leads to degradation of gap junction protein connexin43 in cardiomyocytes. Biochem J. 2015;467:231-45.
29. Martins-Marques T, Catarino S, Marques C, Matafome P, Ribeiro-Rodrigues T, Baptista R, et al. Heart ischemia results in connexin43 ubiquitination localized at the intercalated discs. Biochimie. 2015;112:196-201.
30. Kawaguchi T, Takemura G, Kanamori H, Takeyama T, Watanabe T, Morishita K, et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res. 2012; 96:456-65.
31. Weissgerber TL, Milic NM, Winham SJ, Garovic VD, Cooper R, Schriger D, et al. Beyond bar and line graphs: time for a new data presentation paradigm. PLoS Biol. 2015;13: e1002128.
32. Lötvall J, Hill AF, Hochberg F, Buzás EI, Vizio D Di, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913, doi: http:// dx.doi.org/10.3402/jev.v3.26913
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
34. Hawat G, Benderdour M, Rousseau G, Baroudi G. Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflugers Arch. 2010;460: 583-92.
35. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 2003;4:67-79.
36. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9-18.
37. Chen GG, Lai PBS, Hu X, Lam IKY, Chak ECW, Chun YS, et al. Negative correlation between the ratio of Bax to Bcl-2 and the size of tumor treated by culture supernatants from Kupffer cells. Clin Exp Metastasis. 2002;19:457-64.
38. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-25.
39. Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, et al. Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. Am J Physiol Heart Circ Physiol. 2010;298:H1832-41.
40. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001;108:585-90.
41. Martins-Marques T, Catarino S, Marques C, Pereira P, Girão H. To beat or not to beat: degradation of Cx43 imposes the heart rhythm. Biochem Soc Trans. 2015;43:476-81.
42. Radić J, Krušlin B, Šamija M, Ulamec M, Milošević M, Jazvić M, et al. Connexin 43 expression in primary colorectal carcinomas in patients with Stage III and IV disease. Anticancer Res. 2016;36:2189-96.
43. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-89.
44. Pecoraro M, Sorrentino R, Franceschelli S, Del Pizzo M, Pinto A, Popolo A. Doxorubicin-mediated cardiotoxicity: role of mitochondrial connexin 43. Cardiovasc Toxicol. 15: 366-76.
45. Zhang X, Teodoro JG, Nadeau JL. Intratumoral golddoxorubicin is effective in treating melanoma in mice. Nanomedicine. 2015;11:1365-75.
46. Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282.